BACKGROUND: Pain and depression are each prevalent among opioid dependent patients receiving maintenance buprenorphine, but their interaction has not been studied in primary care patients. OBJECTIVE: We set out to examine the relationship between chronic pain, depression, and ongoing substance use, among persons maintained on buprenorphine in primary care settings. DESIGN: Between September 2012 and December 2013, we interviewed buprenorphine patients at three practice sites. PARTICIPANTS: Opioid dependent persons at two private internal medicine offices and a federally qualified health center participated in the study. MAIN MEASURES: Pain was measured in terms of chronicity, with chronic pain being defined as pain lasting at least 6 months; and in terms of severity, as measured by self-reported pain in the past week, measured on a 0-100 scale. We defined mild chronic pain as pain severity between 0 and 39 and lasting at least 6 months, and moderate/severe chronic pain as severity ≥ 40 and lasting at least 6 months. To assess depression, we used the Center for Epidemiologic Studies Depression (CESD) ten-item symptom scale and the two-item Patient Health Questionnaire (PHQ-2). KEY RESULTS: Among 328 participants, 169 reported no chronic pain, 56 reported mild chronic pain, and 103 reported moderate/severe chronic pain. Participants with moderate/severe chronic pain commonly used non-opioid pain medications (56.3%) and antidepressants (44.7%), yet also used marijuana, alcohol, or cocaine (40.8%) to help relieve pain. Mean CESD scores were 7.1 (±6.8), 8.3 (±6.0), and 13.6 (±7.6) in the no chronic, mild, and moderate/severe pain groups, respectively. Controlling for covariates, higher CESD scores were associated with a higher likelihood of moderate/severe chronic pain relative to both no chronic pain (OR = 1.09, p < 0.001) and mild chronic pain (OR = 1.06, p = 0.04). CONCLUSION: Many buprenorphine patients are receiving over-the-counter or prescribed pain medications, as well as antidepressants, and yet continue to have significant and disabling pain and depressive symptoms. There is a clear need to address the pain-depression nexus in novel ways.
BACKGROUND:Pain and depression are each prevalent among opioid dependent patients receiving maintenance buprenorphine, but their interaction has not been studied in primary care patients. OBJECTIVE: We set out to examine the relationship between chronic pain, depression, and ongoing substance use, among persons maintained on buprenorphine in primary care settings. DESIGN: Between September 2012 and December 2013, we interviewed buprenorphinepatients at three practice sites. PARTICIPANTS: Opioid dependent persons at two private internal medicine offices and a federally qualified health center participated in the study. MAIN MEASURES: Pain was measured in terms of chronicity, with chronic pain being defined as pain lasting at least 6 months; and in terms of severity, as measured by self-reported pain in the past week, measured on a 0-100 scale. We defined mild chronic pain as pain severity between 0 and 39 and lasting at least 6 months, and moderate/severe chronic pain as severity ≥ 40 and lasting at least 6 months. To assess depression, we used the Center for Epidemiologic Studies Depression (CESD) ten-item symptom scale and the two-item Patient Health Questionnaire (PHQ-2). KEY RESULTS: Among 328 participants, 169 reported no chronic pain, 56 reported mild chronic pain, and 103 reported moderate/severe chronic pain. Participants with moderate/severe chronic pain commonly used non-opioid pain medications (56.3%) and antidepressants (44.7%), yet also used marijuana, alcohol, or cocaine (40.8%) to help relieve pain. Mean CESD scores were 7.1 (±6.8), 8.3 (±6.0), and 13.6 (±7.6) in the no chronic, mild, and moderate/severe pain groups, respectively. Controlling for covariates, higher CESD scores were associated with a higher likelihood of moderate/severe chronic pain relative to both no chronic pain (OR = 1.09, p < 0.001) and mild chronic pain (OR = 1.06, p = 0.04). CONCLUSION: Many buprenorphinepatients are receiving over-the-counter or prescribed pain medications, as well as antidepressants, and yet continue to have significant and disabling pain and depressive symptoms. There is a clear need to address the pain-depression nexus in novel ways.
Authors: M Melloh; A Elfering; C Egli Presland; C Röder; P Hendrick; B Darlow; J-C Theis Journal: Occup Med (Lond) Date: 2011-01-03 Impact factor: 1.611
Authors: Michael D Stein; Debra S Herman; Malyna Kettavong; Patricia A Cioe; Peter D Friedmann; Tahir Tellioglu; Bradley J Anderson Journal: J Subst Abuse Treat Date: 2010-07-03
Authors: Andrew Rosenblum; Mark Parrino; Sidney H Schnoll; Chunki Fong; Carleen Maxwell; Charles M Cleland; Stephen Magura; J David Haddox Journal: Drug Alcohol Depend Date: 2007-03-26 Impact factor: 4.492
Authors: Jodie A Trafton; Elizabeth M Oliva; Doyanne A Horst; Jared D Minkel; Keith Humphreys Journal: Drug Alcohol Depend Date: 2004-01-07 Impact factor: 4.492
Authors: Mary Jo Larson; Michael Paasche-Orlow; Debbie M Cheng; Christine Lloyd-Travaglini; Richard Saitz; Jeffrey H Samet Journal: Addiction Date: 2007-05 Impact factor: 6.526
Authors: Kelly E Dunn; Patrick H Finan; D Andrew Tompkins; Michael Fingerhood; Eric C Strain Journal: Drug Alcohol Depend Date: 2015-10-19 Impact factor: 4.492
Authors: Lisa A Uebelacker; Donnell Van Noppen; Geoffrey Tremont; Genie Bailey; Ana Abrantes; Michael Stein Journal: J Subst Abuse Treat Date: 2019-07-24
Authors: Thomas Günther; Pooja Dasgupta; Anika Mann; Elke Miess; Andrea Kliewer; Sebastian Fritzwanker; Ralph Steinborn; Stefan Schulz Journal: Br J Pharmacol Date: 2017-05-26 Impact factor: 8.739
Authors: Dan Werb; Ayden I Scheim; Ayorinde Soipe; Samantha Aeby; Indhu Rammohan; Benedikt Fischer; Scott E Hadland; Brandon D L Marshall Journal: Drug Alcohol Rev Date: 2022-04-18
Authors: Chung Jung Mun; Patrick H Finan; David H Epstein; William J Kowalczyk; Daniel Agage; Janelle E Letzen; Karran A Phillips; Kenzie L Preston Journal: Addiction Date: 2020-12-29 Impact factor: 7.256
Authors: Eman A Alhalal; Ibrahim A Alhalal; Amani M Alaida; Sabreen M Alhweity; Asma Y Alshojaa; Amani T Alfaori Journal: Saudi Med J Date: 2021-03 Impact factor: 1.422